Albireo
Albireo Pharma, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative bile acid modulators aimed at addressing orphan pediatric liver diseases and gastrointestinal disorders. Its leading product, odevixibat, is an ileal bile acid transporter inhibitor currently undergoing phase III clinical trials for conditions such as progressive familial intrahepatic cholestasis, biliary atresia, and Alagille syndrome, among others. The company also develops elobixibat, which is approved in Japan for chronic constipation, and A3384, targeting various gastrointestinal diseases. Additionally, A3907 is a phase I candidate focused on adult liver diseases, while A2342 is in preclinical stages for treating adult viral and liver diseases. Headquartered in Boston, Massachusetts, Albireo Pharma leverages extensive expertise in drug development and maintains a strong network within the scientific and clinical communities.
Biodel Inc. is a development-stage biopharmaceutical company based in Danbury, Connecticut, focused on creating and commercializing innovative treatments for diabetes. The company specializes in applying its proprietary formulation technologies to enhance existing drugs, primarily targeting rapid-acting mealtime insulin for patients with Type I and Type II diabetes through its product candidate, Linjeta. In addition to Linjeta, Biodel is exploring earlier-stage candidates, which include follow-on rapid-acting insulins, a sublingual tablet formulation of insulin known as VIAtab, a range of basal insulins, and a glucagon formulation. Through its proprietary VIAdel technology, Biodel studies the interactions between peptide hormones and small molecules to advance its product development efforts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.